Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Stephen J. Nicholls; Deepak L. Bhatt; John B. Buse; Stefano Del Prato; Steven E. Kahn; A. Michael Lincoff; Darren K. McGuire; Michael A. Nauck; Steven E. Nissen; Naveed Sattar; Bernard Zinman; Sophia Zoungas; Jan Basile; Amy Bartee; Debra L. Miller; Hiroshi Nishiyama; Imre Pávó; Govinda J. Weerakkody; Russell J. Wiese; David A. D’Alessio

doi:10.1016/j.ahj.2023.09.007

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nicholls et al. (2023) studied this question.

synapsesocial.com/papers/69a607599cf1ac82ad736679 https://doi.org/10.1016/j.ahj.2023.09.007

View Full Paper

Ask AI

Bookmark

Share

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Ask about this paper

Abstract

Discussion

Cite This Study

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading